Tarceva (erlotinib HCl, OSI-774 )
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-small-cell Lung
Conditions
Carcinoma, Non-small-cell Lung
Trial Timeline
Nov 1, 2001 → Jan 30, 2004
NCT ID
NCT00036647About Tarceva (erlotinib HCl, OSI-774 )
Tarceva (erlotinib HCl, OSI-774 ) is a phase 3 stage product being developed by Astellas Pharma for Carcinoma, Non-small-cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT00036647. Target conditions include Carcinoma, Non-small-cell Lung.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non-small-cell Lung were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00036647 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoma, Non-small-cell Lung